Brandon Hants - 27 Dec 2023 Form 4 Insider Report for Applied Molecular Transport Inc.

Role
CFO
Signature
/s/ Brandon Hants
Issuer symbol
N/A
Transactions as of
27 Dec 2023
Net transactions value
$0
Form type
4
Filing time
28 Dec 2023, 17:31:33 UTC
Previous filing
28 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMTI Common Stock Disposed to Issuer -301,225 -100% 0 27 Dec 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -150,672 -100% $0.000000* 0 27 Dec 2023 Common Stock 150,672 $2.38 Direct F3
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -4,328 -100% $0.000000* 0 27 Dec 2023 Common Stock 4,328 $4.61 Direct F3
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -20,000 -100% $0.000000* 0 27 Dec 2023 Common Stock 20,000 $14.00 Direct F3
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -76,000 -100% $0.000000* 0 27 Dec 2023 Common Stock 76,000 $56.61 Direct F3
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -57,400 -100% $0.000000* 0 27 Dec 2023 Common Stock 57,400 $8.29 Direct F3
transaction AMTI Stock Option (RIght to Buy) Disposed to Issuer $0 -35,000 -100% $0.000000* 0 27 Dec 2023 Common Stock 35,000 $3.99 Direct F3
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -50,000 -100% $0.000000* 0 27 Dec 2023 Common Stock 50,000 $0.3639 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Brandon Hants is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of Issuer's Common Stock was converted into 0.1331 of a share of Cyclo Common Stock (the "Transaction Consideration").
F2 Upon consummation of the Merger, the Reporting Person received Transaction Consideration of 40,094 shares of Cyclo common stock.
F3 Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
F4 Pursuant to the Merger Agreement, this option was exchanged for an option covering 6,655 shares of Cyclo Common Stock.